Trends & Forecasts

And getting the right people involved from the start. Here’s why collaboration is key for successful clinical development.

Why mRNA will be a key disrupter in the coming years; experts from CureVac and Omega Therapeutics give their views.

Welcome back to our interview series with Jon Thomas, President and CEO of the California Institute for Regenerative Medicine: CIRM.

What lies ahead for the future of pharma? Dennis van Rooji gives his view.

Accelerating the progress of cell and gene therapies with decentralized trials and other innovative approaches.

AI helps make preclinical decisions faster, but stakeholders remain cautious. We asked an expert from Elsevier for their views on the challenges.

New medicines save lives, but they take too long to get to market. Could AI make a difference?

Cell and Gene therapies have come a long way since the 1970s. Technology, combined with knowledge, will take them even further.

Jon Thomas, CEO of CIRM, discusses the evolution of stem cell research and the future of regenerative medicine in this interview.

Personalized medicine, digital therapeutics, and GLP-1s; experts tell us what areas are hot in pharma’s future.